GlassScriptPhysician profile
Stacey C Muhammad
NPI 1366439853
$1,392.17
in general payments reported to CMS, 2019-2025
36 companies · $441 in 2025
The $441 reported for 2025 was more than what 90% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
See the full distribution for Hospice and Palliative Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.57 · 2023: $320 · 2024: $546 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $115.09 | 2023-2025 | Rybrevant, Erleada, Carvykti |
| Daiichi Sankyo INC. | $114.61 | 2024-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $93.17 | 2023-2024 | Enhertu |
| Sobi, INC | $84.01 | 2023-2025 | |
| Taiho Oncology, INC. | $83.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $70.16 | 2023-2024 | Keytruda, Welireg |
| Alexion Pharmaceuticals, INC. | $50.61 | 2022-2024 | Ultomiris |
| Deciphera Pharmaceuticals INC. | $49.88 | 2024 | Qinlock, Tgct |
| Beigene USA, INC. | $49.49 | 2024 | Brukinsa |
| Celgene Corporation | $46.55 | 2024-2025 | Breyanzi |
| Stemline Therapeutics INC. | $40.04 | 2024-2025 | Orserdu |
| Karyopharm Therapeutics INC. | $38.04 | 2022-2023 | Xpovio |
| Syndax Pharmaceuticals, INC. | $31.78 | 2025 | |
| Mirati Therapeutics, INC. | $31.35 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $31.02 | 2023 | Libtayo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.35 | 2025 | |
| Tersera Therapeutics LLC | $26.96 | 2024 | Zoladex |
| Apellis Pharmaceuticals, INC. | $26.77 | 2024 | Empaveli |
| Abbvie INC. | $26.11 | 2023 | |
| G1 Therapeutics, INC. | $24.71 | 2022 | |
| Sumitomo Pharma America, INC. | $24.21 | 2025 | Orgovyx |
| Lilly USA, LLC | $23.43 | 2023 | Verzenio, Jaypirca, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $23.26 | 2025 | Opdivo |
| Gilead Sciences, INC. | $23.11 | 2023 | Trodelvy |
| Glaxosmithkline, LLC. | $22.87 | 2023 | |
| Rigel Pharmaceuticals, INC. | $21.57 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Genentech USA, INC. | $20.95 | 2025 | Itovebi |
| Emd Serono, INC. | $20.83 | 2024 | |
| Pharmaand Gmbh | $20.74 | 2025 | Rubraca |
| Tolmar, INC. | $20.74 | 2025 | Eligard, Rubraca |
| Alnylam Pharmaceuticals INC. | $20.68 | 2023 | Givlaari |
| Blueprint Medicines Corporation | $19.39 | 2022 | |
| Exelixis INC. | $18.06 | 2024 | Cabometyx |
| Pfizer INC. | $17.89 | 2024 | |
| Recordati_rare_diseases_inc. | $17.21 | 2025 | Enjaymo |
| Incyte Corporation | $13.70 | 2024 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Muhammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.